Bausch + Lomb Announces Webinar for Eye Care Professionals on New AREDS2 Study Results

ByMartha R. Camara

Sep 21, 2022

VAUGHAN, ON, September 21, 2022 /CNW/ — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better , today announced that data from the National Eye Institute (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), recently published in JAMA Ophthalmology, will be reviewed and discussed among leading eye care professionals in a free live webinar,”More information: a closer look at the new AREDS2 data and what it means for patients” on Tuesday, October 18, 2022of 8:00-9:00 p.m. ET.

Bausch + Lomb (PRNewsfoto/Bausch + Lomb Corporation)

The hour-long webinar is specifically designed to help eye care professionals understand the new findings and learn how they can be incorporated into practice to support patients with age-related macular degeneration (AMD). The session, which will be moderated by Paul Karpecki, OD, Clinical Director, Kentucky Eye Institute, will also highlight clinical insights from Emily ChewMD, Chair, AREDS2 Study, NEI, and present expert commentary from panelists Jeffry GersonOD, Grin Eye Care, Kansas City, Mo.and Rishi SinghMD, Chairman, Cleveland Clinic Martin North and South Hospitals, Cleveland.

“With the AREDS2 10-year follow-up study, we now have more than two decades of research demonstrating the impact a specific nutrient formula can have on patients with moderate to advanced AMD,” Dr. Chew said. “The purpose of the ‘More InSight’ webinar is to discuss this impact – which further supports NEI’s current recommendation of a specific combination of six nutrients, including lutein, zeaxanthin and antioxidants, and how physicians can put implement these learnings in daily practice.

“Along with Drs Chew, Gerson, Karpecki and Singh, we look forward to providing eyecare professionals with the opportunity to learn more about these latest research findings as well as gain some insightful takeaways that can improve their AMD practices and support the millions of people affected by moderate to advanced AMD,” said Joe Gordon, president, Global Consumer, Surgical and Vision Care, Bausch + Lomb.

To register for the “More InSight” webinar, go to www.reviewofophthalmology.com/more-insight-1018.

About AMD
Age-related macular degeneration (AMD) is a progressive eye condition that affects central vision and is a leading cause of blindness in adults aged 50 and over. Early-stage AMD often has no symptoms or changes in vision, as symptoms usually appear gradually over time. This progressive condition can affect one eye or both eyes, making people having difficulty in daily activities like driving, reading, or recognizing the faces of loved ones.2

About the results of the AREDS, AREDS2 and 10-year follow-up AREDS2 studies
The AREDS and AREDS2 studies are benchmark clinical studies conducted for 20 years by the NEI. The 2001 AREDS study demonstrated that taking a specific combination of antioxidants and zinc could help reduce the risk of AMD progression in people with moderate to advanced AMD. In 2012, the NEI completed the AREDS2 study, which tested several formulation modifications, such as adding omega-3 fatty acids, substituting lutein and zeaxanthin for beta-carotene, and/or reducing zinc. The current AREDS2 nutrient formula recommended by the NEI is the result of this study.

Results from the NEI 10-year follow-up study assessed the long-term outcomes of participants who participated in the AREDS2 study. Comprised of 3,883 people (6,351 study eyes) with moderate to advanced AMD over a 10-year period, the follow-up study further validates the original results of the AREDS2 formulation with lutein and zeaxanthin, demonstrating a gradual reduction in the risk of progression to advanced AMD.1

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every stage of life. Its comprehensive portfolio of over 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products, and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and sales footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, ON with headquarters in Bridgewater, New Jersey. For more information, visit www.bausch.com and contact us at TwitterLinkedIn, Facebook and Instagram.

Forward-looking statements
This press release may contain forward-looking statements, which can generally be identified by the use of the words “anticipates”, “hopes”, “expects”, “intends”, “expects”, “should ‘, ‘could’, ‘would’, ‘may’, ‘believes’, ‘estimates’, ‘potential’, ‘target’ or ‘continues’ and similar variations or expressions. These statements are based on management’s current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the United States Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated into present by reference. They also include, but are not limited to, the risks and uncertainties caused by or related to the evolution of the COVID-19 pandemic, as well as the fear of this pandemic and its potential effects, including the severity, duration and future impact are highly uncertain and cannot be predicted, and which could have a material adverse impact on Bausch + Lomb, including, but not limited to, delays in the development of its projects, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual results, except as required by law.

*Compared to patients taking the original AREDs formula

References

  1. Chew EY, Clemons TE, Agron E, et al. Long-term results of adding lutein/zeaxanthin and ω-3 fatty acids to AREDS supplements on progression of age-related macular degeneration: AREDS2 report 28. JAMA Ophthalmology. 2022;140(7):692–698. doi:10.1001/jamaophthalmol.2022.1640National Eye Institute: Macular degeneration.

  2. Based on AREDS and AREDS2 studies.

AREDS and AREDS2 are registered trademarks of the US Department of Health and Human Services (HHS).
All other product/brand names are trademarks of their respective owners.
© 2022 Bausch & Lomb Incorporated or its affiliates.
PV2.0108.USA.22

Investor contacts:

Media contacts:

Arthur Shanon

Lainie Keller

[email protected]

[email protected]

(908) 927-1198

Allison Ryan

Kristy Marks

[email protected]

[email protected]

(877) 354-3705 (toll free)

(908) 927-0683

(908) 927-0735

Quote

Quote

View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch–lomb-announces-webinar-for-eye-care-professionals-on-new-areds2-study-findings- 301629071. html

SOURCEBausch + Lomb Corporation

Quote

Quote

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2022/21/c4852.html